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Background: Patients with systemic lupus erythematosus (SLE) are 5–8 times more likely 
to develop coronary heart disease than the general population. The aim of this study was to 
find out the prevalence of the small dense low-density lipoprotein (LDL) cholesterol particle 
in patients with SLE.
Methods: We recruited 50 consecutive patients with SLE who had no evidence of hypertension 
or renal failure. Fifty age- and gender-matched healthy controls were also recruited. We measured 
serum lipid levels and LDL particle diameters by gradient gel electrophoresis in both patients 
and controls.
Results: Patients with SLE had significant dyslipidemia, characterized by elevated plasma 
triglycerides, LDL cholesterol, Apoprotein B, triglyceride:high-density (HDL) lipoprotein 
cholesterol ratio, and decreased plasma concentrations of HDL cholesterol. The LDL particle 
size in SLE (24.8 ± 1.23 nm) was significantly (P , 0.01) smaller than that in controls 
(26.1 ± 1.31 nm). The prevalence of the LDL phenotype B (the atherogenic phenotype) was 
52% in SLE but only 20% in healthy controls.
Conclusion: We conclude that the high prevalence of small dense LDL in SLE may contribute 
to the high incidence of coronary heart disease seen in this disorder.
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Introduction
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by 
the activation of T and polyclonal B lymphocytes, the production of autoantibodies, and 
the formation of immune complexes causing tissue and organ damage.1,2 Although its 
exact etiology is unknown, its clinical consequences can be devastating. For example, 
in prospective cohorts where incidence cases have been recorded, the prevalence of 
coronary heart disease in SLE has been 6%–10%3–5 and the estimated incidence of new 
coronary heart disease events is approximately 1.2%–1.5% per annum. Manzi et al1 
utilized data from the Pittsburgh lupus cohort and compared them with data from 
women followed in the Framingham Offspring study. Overall, women with SLE had 
a 5–6-fold increased risk of coronary heart disease. Moreover, women with SLE aged 
35–44 years were 52 times more likely to develop coronary heart disease. Employing 
data from the California Discharge Database, Ward5 found that women with SLE 
aged 18–44 years were more likely than aged-matched controls to have myocardial 
infarction, congestive heart failure, or stroke. Extrapolating from the population 
  prevalence of SLE, Ward estimated that, overall, myocardial infarction, heart   failure, 
and stroke were 8.5, 13.2, and 10.1 times more likely in women with SLE. In a Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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case-control study from the UK General Practice Research 
Database, Fischer et al6 also reported that patients with SLE 
were at higher risk of developing coronary heart disease.
The pathogenesis of coronary heart disease in SLE is likely 
to be multifactorial, and may be related to vasculitis, corti-
costeroid use, renal disease, hypertension, hyperlipidemia, 
or thrombosis associated with antiphospholipid antibodies. 
Patri et al2 reported that patients with SLE were more likely to 
have a sedentary lifestyle, obesity, and hypercholesterolemia, 
while Borha et al7,8 found that, compared with   controls, 
patients with SLE had lower high-density   lipoprotein 
(HDL) cholesterol as well as higher very low-density 
lipoprotein (VLDL) cholesterol, triglycerides, and lipo-
protein (a)   concentrations. Increased carotid intima thickness, 
increased plasma concentrations of circulating oxidized LDL 
and homocysteine, as well as endothelial defects, have all 
been incriminated in the premature coronary heart disease 
seen in patients with SLE.9–11
Human plasma low-density lipoproteins (LDL) are a 
heterogenous collection of particles which vary in buoyant 
density, size, and lipid and protein composition.12–14 Small-
sized LDL cholesterol has been associated with coronary 
heart disease in some case-control studies,15–18 although other 
studies have not found this association.19,20
There are only two reports in the literature on LDL 
particle size in SLE. Using nuclear magnetic resonance 
to measure LDL particle sizes in patients with SLE, both 
Chung et al21 and Hua et al22 did not find any differences in 
small dense LDL particle size between patients with SLE 
and controls. Therefore, we decided to use a different method 
to measure LDL particle size in 50 patients with SLE and 
50 healthy controls. We measured LDL particle diameters 
by gradient gel electrophoresis (Quantimatrix LipoprintTM 
LDL System, Quantimetrix Corporation, Redondo Beach, 
CA) in both patients and controls.
Methods and materials
subjects
Fifty patients (all women) meeting the 1997 revised criteria 
of the American College of Rheumatology for SLE were 
recruited from the rheumatology clinic at the Al-Amiri 
Teaching Hospital in Kuwait over a period of one year from 
December 2005–  December 2006. Inclusion criteria were 
disease onset at age ,18 years and current age .22 years. 
Exclusion criteria were pregnancy, use of lipid-lowering 
drugs, current smoking, proteinuria, a plasma creatinine 
concentration .120 µmol/L, abnormal liver function, and a 
  fasting plasma glucose .6.1 mmol/L. At initial   presentation, 
the disease   activity of each patient was assessed by the SLE 
Disease Activity Index. The patients were then treated with glu-
cocorticoid and/or i  mmunosuppressive agents until they were 
stable. Fifty age-matched healthy   controls (again all women) 
were also recruited. The controls were matched with the SLE 
patients for body mass index (BMI). Informed consent was 
obtained from each participant before the study. The protocol 
for the study was approved by the local ethics committee.
collection of blood samples
Following an overnight 12-hour fast (9 pm–9 am), 10 mL of 
blood was collected in citrated containers from each patient 
(before and after treatment) and control, and plasma was 
separated and kept frozen at −80°C until ready for analysis. 
The following tests were done on plasma samples from 
patients (before and after treatment) and controls.
Laboratory analysis
Erythrocyte sedimentation rate was measured using a 
modified Westergren method. Anti-double-stranded DNA 
antibody levels were measured using a commercial enzyme-
linked immunoassay kit (Inova Diagnostics, San Diego, CA). 
The Beckman LX20 automated analytical system (Beckman-
Coulter, Brea, CA) was used to measure glucose by the 
hexokinase method, total cholesterol and HDL cholesterol 
by the cholesterol esterase method, and triglycerides by the 
lipase method. Apolipoprotein B (ApoB) was measured by a 
nephelometric method on a Beckman IMMAGE automated 
analytical system (Beckman-Coulter). LDL cholesterol was 
calculated from total cholesterol, HDL-cholesterol, and 
  triglyceride values using the formula, LDL cholesterol = total 
cholesterol-HDL-triglycerides/2.2.23
LDL subclass analysis
A modified tube gel electrophoresis technique, the Lipoprint 
System (Quantimetrix Corporation)24 was used. A serum 
sample (25 µL) was applied to the “ready to use” polyacryl-
amide gel tube along with 200 µL of a loading gel solution 
containing a lipophilic dye. The sample loading gel mixture 
was photopolymerized for 30 minutes prior to electropho-
resis at a constant of 3 mA/tube for one hour. This system 
resolved up to 12 serum lipoprotein fractions as follows: 
VLDL (1), mid-band (3), LDL (7), and HDL (1). HDL 
migrated the fastest (retention factor [Rf] = 1), while VLDL 
migrated the slowest to the top of gel (Rf = 0). Mid-band and 
LDL   subfractions migrated at various Rfs between VLDL 
and HDL. Lipoware computer software (Quantimetrix 
Corporation) was used to analyze the gel images. The bands Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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were partitioned into d  iscrete segments, and the relative 
area under the curve calculated for each lipoprotein band. 
The program also calculated the cholesterol concentration 
for each lipoprotein f  raction using a total cholesterol value 
obtained for each sample by the routine assay mentioned 
under analysis.
Using the Lipoprint method, VLDL remained at the origin 
(Rf = 0.0), whereas HDL migrated at the front (Rf = 1.0). 
In between, several bands could be detected, ie, mid-bands 
C, B, and A, which corresponded mainly to intermediate-
density lipoproteins, as well as up to seven LDL bands. The 
LDL1 and LDL2 bands corresponded to large buoyant LDL 
particles, whereas bands LDL3–7 corresponded to small 
dense LDL particles. According to the LDL electrophoretic 
profile, two phenotypes are defined, ie, A and non-A. The 
LDL particle size was estimated using the Lipoprint System 
by means of the algorithm developed by Kazumi et al.25 The 
size cutoff was $26.8 nm for phenotype A (normal LDL size) 
and less than this for non-A (designated as phenotype B). 
It is likely that the temperature gradient gel electrophoresis 
method overestimated LDL particle size in comparison with 
other methods and, therefore, this method’s size cutoff is 
probably equivalent to the gradient gel electrophoresis cutoff 
of 25.7 nm for small dense LDL.26
Quality control
The internal quality of routine analyses was monitored at 
two levels of concentration, ie, normal and   pathological. 
Glucose and lipid parameters were included in the 
Kuwait National and Biorad external quality assurance 
schemes. For LDL subclass analysis, the quality control 
  material (  Liposure) used was obtained from Quantimetrix 
  Corporation, the   manufacturers of the Lipoprint gel tube 
electrophoresis system.
Data analysis
Assessment of differences between the means, correlations 
between chosen parameters, and regression analyses were 
carried out using SPSS 15 for Windows. Significance was 
set at the level of P , 0.05.
Results
Table 1 shows that patients with SLE and healthy controls 
were well matched with respect to age, gender, hyperten-
sion, BMI, and fasting blood sugar. This was done to 
eliminate these parameters as confounding variables in 
the analysis of the lipid data. Compared with controls, 
patients with SLE had significantly higher plasma total 
c  holesterol (6.62 ± 0.84   versus 5.24 ± 0.64 mmol/L), LDL 
  cholesterol (4.72 ± 0.68 versus 3.30 ± 0.53 mmol/L), trig-
lycerides (2.53 ± 0.24 versus 1.85 ± 0.18 mmol/L), Apo B 
(0.96 ± 0.18 versus 0.73 ± 0.10 mmol/L), and triglyceride:HDL 
cholesterol ratio (3.29 ± 0.42 versus 1.68 ± 0.31), but had 
  significantly lower plasma HDL cholesterol (0.77 ± 0.22 
  versus 1.10 ± 0.23 mmol/L) and LDL particle size (24.8 ± 1.23 
versus 26.1 ± 1.31 nm) than healthy controls. The LDL sub-
class analysis showed that 26 of the 50 patients with SLE 
were phenotype B, while only 10 of the 50 healthy controls 
were phenotype B. The remaining 24 of the SLE patients 
and 40 of the healthy controls were phenotype A. Thus, the 
prevalence of the LDL phenotype B among patients with SLE 
was 52% and was only 20% among healthy controls. This 
difference was statistically significant (P , 0.01). Figures 1 
and 2   represent pattern A and B, respectively.
Discussion
We have demonstrated in this study that our patients with 
SLE had significantly higher plasma concentrations of VLDL, 
triglycerides, LDL, and ApoB, but lower plasma HDL than 
Table 1 Demographic and metabolic characteristics of patients with sLe and healthy controls
Characteristics Patients with SLE (mean ± SD) Control (mean ± SD) P value
Age (sD) years 50.3 ± 8.6 49.6 ± 7.2 ns
Hypertension, % 10 0 ns
Fasting plasma glucose (sD), mmol/L 6.4 ± 0.38 6.2 ± 0.35 ns
Plasma total cholesterol (sD), mmol/L 6.62 ± 0.84 5.24 ± 0.64 ns
Plasma HDL-c (mmol/L) 0.77 ± 0.22 1.10 ± 0.23 ,0.01
Plasma LDL-c (mmol/L) 4.72 ± 0.68 3.30 ± 0.53 ,0.01
Plasma triglycerides (sD) mmol/L 2.53 ± 0.24 1.85 ± 0.18 ,0.05
Plasma Apoprotein B (mmol/L) 0.96 ± 0.18 0.73 ± 0.10 ,0.05
Triglyceride/HDL-c ratio 3.29 ± 0.42 1.68 ± 0.31 ,0.001
LDL particle size (nm) 24.8 ± 1.23 26.1 ± 1.31 ,0.01
Plasma creatinine (µmol/L) 76.53 ± 8.2 66.1 ± 1.31 ns
Abbreviations: sD, standard deviation; sLe, systemic lupus erythematosus; HDL-c, high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol; ns, 
not significant.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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healthy controls. Two distinct types of dyslipoproteinemia 
in SLE have been described in the literature. The first type 
is characterized by high levels of VLDL triglycerides and 
VLDL cholesterol, and low levels of HDL. This lipid profile 
is usually seen in untreated or inactive SLE, but can also be 
seen in patients with active disease.27-30 Our patients fall into 
this category. Little is known about the mechanisms behind 
this lipid disorder, although decreased activity of endothelial 
lipoprotein lipase and impaired chylomicron removal from 
plasma29 are two factors present in SLE patients which may 
contribute to elevations of triglycerides. Antibodies to ApoA1 
are also detected in some SLE patients and may contribute 
to low levels of HDL.30,31 However, we did not estimate 
antibodies to ApoA1 in our patients. The second pattern of 
lipid disturbance often seen in SLE arises as a complication 
of steroids.32 Steroid treatment induces an increase in total 
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Figure 1 The densitometric scan of LDL subfraction (Pattern A) obtained in controls.
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cholesterol (including both LDL and HDL) and a more   modest 
elevation of triglycerides.33 Patients with renal disease also 
have increased levels of total and LDL cholesterol, together 
with triglycerides and HDL. It is unlikely that our patients 
had renal disease because none of them had proteinuria or a 
plasma creatinine concentration .120 µmol/L.
We have demonstrated using the Lipoprint LDL system 
that patients with SLE have a smaller denser LDL particle 
size than healthy controls. The generation of small dense 
LDL particles occurs due to elevation of mild to moderate 
hyperglyceridemia.34 Under these conditions, triglycerol-
rich VLDL increases due to overproduction in the liver or 
defective clearance from the circulation. Cholesteryl ester 
transfer protein removes cholesteryl ester and replaces it 
with triacylglycerol as the protein shuttles between VLDL, 
LDL, and HDL particles. Triacylglycerol-enriched LDL is 
a better substrate for hepatic lipase, which removes triacyl-
glycerol from small lipoprotein particles. When the hepatic 
lipase activity is high enough, lipolysis generates smaller 
and denser LDL particles. LDL oxidation is an important 
factor in atherosclerosis, and small dense LDL particles 
are easier to oxidize than larger, less dense particles. As a 
result of oxidation, a variety of immunogenic neoepitopes 
are formed on the oxidized LDL. For example, oxidation of 
  phosphorylcholine containing phospholipids renders them 
antigenic. Oxidized LDL forms ligands on oxidized LDL 
particles recognized by macrophages, leading to enhanced 
uptake of oxidized LDL particles and foam cell formation.36–38 
Through this route, macrophages become lipid-laden and 
develop into the characteristic foam cells of atherosclerotic 
lesions. Oxidized LDL is also chemotactic, immunostimula-
tory, and has toxic properties that promote local inflammatory 
processes in atherosclerotic lesions.39,40 Furthermore, oxidized 
LDL elicits a humoral immune response with production of 
autoantibodies to oxidation-specific epitopes of oxidized 
LDL. Therefore, the presence of small dense LDL subfrac-
tions in patients with SLE may be an independent risk factor 
for the development of premature atherosclerosis.
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